RE:Slo Walking TH1902 Trial? I believe previously I was referring to initial start and the time line for it as many thought it was going to slow or it was delayed but as per my take based on the initial design it would take as long as it did until the stop! The restart has a part 3, 6+6+4 patients and part 4 total 20 patients including among others if available patients from parts 1, 2 and 3. When would they be able to announce the results would be based on the enrolment progress and of course the results. I would hope that if the results are positive they would share it as soon as they can. Point is the valuation now has issues because the costs associated with the oncology trial is priced in it, so does weak balance sheet, potential Marathon issues and weaker than anticipated sales so far. If and when there is any progress in oncology, potential renegotiation with Marathon which is not short termed and better sales etc. any of those could and should improve the market's perception of company's value. Ideally as many have suggested they should cut the costs ASAP and in my opinion that process should include less populated board of directors and wage cuts of management including the CEO's hefty salary which the company specifically now can't afford. I guess what I am trying to say is the valuation is trashed not only because of the pessimism about the oncology but also the financial health of the company.
Lee430 wrote: Scarlet,
Previously you mentioned that you thought the TH1902 trial was let’s say (Slo Walking) and their timelines looked too aggressive.
That assessment sure seems to be pretty accurate now as they are almost a month past the stated start date, so when would you think we could see a PR announcing patients’ dosage has started? Would the end of August be too optimistic?